MIG AG

MIG Verwaltungs AG (MIG AG) is one of the leading German VC Investors. MIG invests in deep technology from early to later stage. MIG Verwaltungs AG (MIG AG) uses investments to shape a better tomorrow, today. They manage MIG Fonds, funds used to finance entrepreneurs and start-up businesses in various stages of development. As a venture capital investor, they have already funnelled nearly 500 million Euro into start-up ventures and as such have helped more than 30 outstanding business ideas become a reality. MIG currently manages 15 MIG public venture funds regulated by BAFIN with a total of > 900 Mio Euro of committed capital from more than 50.000 private investors. MIG is currently invested in a portfolio of 24 companies.

Boris Bernstein

Venture Partner

Klaus Feix

Venture Partner

Matthias Guth

Venture Partner

Sören Hein

Partner

Oliver Kahl

Principal

Jürgen Kosch

General Partner

Matthias Kromayer

General Partner

Michael Motschmann

General Partner

Kristian Schmidt-Garve

General Partner

85 past transactions

Siltectra

Series A in 2013
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.

Protagen

Series B in 2006
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Sovicell GmbH

Venture Round in 2009
Sovicell is dedicated to providing trusted state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) products and services that enable their customers to rapidly obtain accurate and reproducible pharmacokinetic data about their drug candidates or other test substances.

Sovicell GmbH

Series D in 2007
Sovicell is dedicated to providing trusted state-of-the-art ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicology) products and services that enable their customers to rapidly obtain accurate and reproducible pharmacokinetic data about their drug candidates or other test substances.

Biocrates Life Sciences

Venture Round in 2010
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

wealthpilot

Venture Round in 2021
We believe in wealth management democratization. We believe that everyone should be able to control their financial life and reach their financial goals. We do that by combining simple-to-use technology with professional personal advice for all financial assets. Our Software-as-a-Service Platform automatically analyzes and plans all types of assets and enables professional advisors to deliver a data-driven and truly personal wealth management.

NFON

Venture Round in 2012
NFON AG, a Munich, Germany-based provider of outsourced telephone systems. nfon's outsourced telephone systems, called IP Centrex, are offered as a complete package from a single source. Operated by a fully redundant, high-performance computer centre and with more than 100 functions, the solution is designed to enable companies of all sizes to save up to 50% percent of the costs for a conventional phone system.

NavVis

Series C in 2018
NavVis is the leading global provider of indoor spatial intelligence solutions for enterprises, trusted by top companies including Daimler, Allianz, Huawei, Lenovo and Deutsche Telekom. NavVis helps enterprises drive efficiencies and optimize business performance through its open digital twin platform that enables accurate mapping at unprecedented speed and scale, immersive 3D visualization designed for collaboration and location-based apps that pioneer AI-powered positioning technology. Founded in 2013, NavVis is headquartered in Munich and has offices in New York and Shanghai.

PDC Biotech

Series A in 2010
PDC Biotech GmbH (PDC) is a private biopharmaceutical company developing innovative therapeutics for the treatment of preterm labour and primary dysmenorrhea, two areas of significant unmet medical need and large market potential. The primary focus for the company is the development of a pipeline of products which are antagonists of the receptor for prostaglandin F2α (FP receptor). PDC has licensed exclusive worldwide rights to a family of FP receptor antagonists from Theratechnologies Inc. (www.theratech.com) which include both peptides (compounds composed of at least two amino acids) and peptidomimetics (peptide-like compounds).

KONUX

Series B in 2019
KONUX is a German AI scale-up, transforming railway operations for a sustainable future. We combine Machine Learning and IoT to make railway the mobility choice of tomorrow by increasing capacity, reliability, and cost-efficiency. Since its foundation in 2014, KONUX has raised more than $50 million from world-leading investors, expanded to multiple countries in Europe and Asia, and was selected by the World Economic Forum (WEF) as one of the world’s 30 most innovative start-ups and scale-ups worldwide.

Isarna Holding GmbH

Venture Round in 2011
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Cynora

Series C in 2019
cynora GmbH develops and manufactures organic electronics. The company develops organic light-emitting diodes, blue OLED emitters systems, and organic solar cells that enable reduction in power consumption of OLED devices. It offers materials that are able to convert triplet excitons into light via Thermally Activated Delayed Fluorescence (TADF) to reduce electrical stress within the OLED and caters to AMOLED markets. The company was founded in 2008 and is headquartered in Bruchsal, Germany.

Efficient Energy

Venture Round in 2015
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

Cynora

Series A in 2011
cynora GmbH develops and manufactures organic electronics. The company develops organic light-emitting diodes, blue OLED emitters systems, and organic solar cells that enable reduction in power consumption of OLED devices. It offers materials that are able to convert triplet excitons into light via Thermally Activated Delayed Fluorescence (TADF) to reduce electrical stress within the OLED and caters to AMOLED markets. The company was founded in 2008 and is headquartered in Bruchsal, Germany.

IDENT Technology

Venture Round in 2011
IDENT Technology AG provides technology solutions for working with e-fields in near-field communication and gesture controlled human-machine-interface. It markets its SKINPLEX technologies for detection, interaction, and identification applications in the capacitive near field and the gesture supported human-machine control applications in the form of licenses. The company offers SKINPLEX GestIC for gesture detection applications; SKINPLEX zeropower sensor system, a quasi powerless near-field transponder system for touchless sensing applications in rough environments; and SKINPLEX ultra-low-power proximity system, which provides the solution to wake-up and power down devices on the approach and the departure of the user. It serves consumer electronics, white good, building management, health care, telecommunication, gaming, toys, and automotive Industries. The company was founded in 2002 and is based in Wessling, Germany.

BioNTech

Series A in 2018
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

SuppreMol

Series D in 2012
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Hemovent

Series A in 2016
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

Efficient Energy

Seed Round in 2008
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

KONUX

Series A in 2017
KONUX is a German AI scale-up, transforming railway operations for a sustainable future. We combine Machine Learning and IoT to make railway the mobility choice of tomorrow by increasing capacity, reliability, and cost-efficiency. Since its foundation in 2014, KONUX has raised more than $50 million from world-leading investors, expanded to multiple countries in Europe and Asia, and was selected by the World Economic Forum (WEF) as one of the world’s 30 most innovative start-ups and scale-ups worldwide.

SuppreMol

Series B in 2008
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Biocrates Life Sciences

Venture Round in 2019
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

Isarna Holding GmbH

Private Equity Round in 2005
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Efficient Energy

Venture Round in 2018
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

Efficient Energy

Venture Round in 2011
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

Temedica

Series B in 2020
Temedica aims to revolutionize the way healthcare is delivered - through digitization. This opens up a variety of opportunities to increase efficiency, quality and transparency and caters to the interests of stakeholders across the board. Temedica builds digital products that aspire to enhance the quality of care for the patient while cutting costs for the healthcare system.

IQM Finland Oy

Seed Round in 2019
IQM Finland Oy develops and manufactures hardware systems for quantum computing solutions for practical applications. The company manufactures quantum processors for quantum computers. IQM Finland Oy was founded in 2018 and is headquartered in Espoo, Finland.

SuppreMol

Series D in 2013
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Siltectra

Series A in 2014
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.

AMSilk

Series B in 2011
AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.

German Bionic

Series A in 2020
GBS German Bionic Systems GmbH develops and manufactures exoskeleton devices for use in industrial production. The company offers German Bionic CRAY X, a wearable human-robotic exoskeleton, which supports users in various industries while manual handling of goods and tools. It deploys micro mechanical components and an ergonomic, lightweight carrying system which allows a comfortable wearing of the exoskeleton. The company was founded in 2016 and is headquartered in Augsburg, Germany with additional offices in Berlin, Germany; and Tokyo, Japan.

advanceCOR

Venture Round in 2018
advanceCOR is a clinical drug developing company that focuses on therapeutics and diagnostics for heart and vascular diseases. Its products include Revacept, a human Fc fusion protein, which prevents the local activation of platelets at sites of vascular injury; COR-2, a recombinant protein that interferes with the generation of foam cells; and COR-3, a recombinant protein, which specifically binds to atherosclerotic plaques, and then bi-specifically binds to circulating progenitor cells to trap the endogenously occurring progenitor cells for accelerated plaque healing.

AFFiRiS

Venture Round in 2011
AFFiRiS AG develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases with unmet medical needs. Its development portfolio includes vaccines against Alzheimer’s disease, Parkinson’s disease and atherosclerosis, multiple system atrophy, hypertension, diabetes, psoriasis, allergies, asthma, Huntington’s disease, and other diseases. The company was founded in 2003 and is based in Vienna, Austria.

Protagen

Venture Round in 2009
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

KONUX

Series B in 2018
KONUX is a German AI scale-up, transforming railway operations for a sustainable future. We combine Machine Learning and IoT to make railway the mobility choice of tomorrow by increasing capacity, reliability, and cost-efficiency. Since its foundation in 2014, KONUX has raised more than $50 million from world-leading investors, expanded to multiple countries in Europe and Asia, and was selected by the World Economic Forum (WEF) as one of the world’s 30 most innovative start-ups and scale-ups worldwide.

KEWAZO

Seed Round in 2018
KEWAZO GmbH develops robotics systems that enable the autonomous transport of materials on the construction site in vertical and horizontal dimensions for large scaffolding companies and industrial service providers. It provides a safe assembly transport of scaffolding parts by delivering parts just-in-time and just-in-place during assembly. The company was founded in 2016 and is based in Gilching, Germany.

Ganymed Pharmaceuticals

Series D in 2008
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

IOmx Therapeutics

Series B in 2021
iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action. The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.

Isarna Holding GmbH

Venture Round in 2007
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Liva Healthcare

Series B in 2021
Founded in 2014, Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management. Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe' at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England and AXA PPP Healthcare. Liva Healthcare’s platform facilitates ongoing personalised health coaching through an intuitive app, building strong bond between coach, GP and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity and heart disease by driving behaviour change. The app is multilingual across several languages, proven to work efficiently across all socio-economic backgrounds and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviours stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes. Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform or as a turn-key solution, dependent on client specifications. Liva Healthcare has offices in Copenhagen, Denmark and London, UK.

Efficient Energy

Venture Round in 2019
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

Siltectra

Seed Round in 2012
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.

AFFiRiS

Venture Round in 2016
AFFiRiS AG develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases with unmet medical needs. Its development portfolio includes vaccines against Alzheimer’s disease, Parkinson’s disease and atherosclerosis, multiple system atrophy, hypertension, diabetes, psoriasis, allergies, asthma, Huntington’s disease, and other diseases. The company was founded in 2003 and is based in Vienna, Austria.

BRAIN

Private Equity Round in 2012
BRAIN offers the full scope of bio-based solutions. BRAIN is a pioneer of industrial biotechnology. They create innovative solutions applying a world class biotechnology toolkit to their BioArchive, a proprietary repository of natural compounds. Focused on delivering solutions to their customers’ application needs they deliver value from concept to commercialization and beyond.

Biocrates Life Sciences

Series A in 2006
Biocrates is a developer of a metabolomics platform designed to support the discovery and validation of biomarkers for complex diseases. The company's metabolomics platform comprises an automated sample preparation workflow integrated with sensitive mass-spectrometric methods and software that controls sample management, data collection, and analysis to identify hundreds of metabolites, enabling physicians to acquire comprehensive metabolic information quickly and reliably.

Corimmun

Series A in 2008
Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.

Protagen

Venture Round in 2014
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

NavVis

Series A in 2014
NavVis is the leading global provider of indoor spatial intelligence solutions for enterprises, trusted by top companies including Daimler, Allianz, Huawei, Lenovo and Deutsche Telekom. NavVis helps enterprises drive efficiencies and optimize business performance through its open digital twin platform that enables accurate mapping at unprecedented speed and scale, immersive 3D visualization designed for collaboration and location-based apps that pioneer AI-powered positioning technology. Founded in 2013, NavVis is headquartered in Munich and has offices in New York and Shanghai.

KEWAZO

Series A in 2021
KEWAZO GmbH develops robotics systems that enable the autonomous transport of materials on the construction site in vertical and horizontal dimensions for large scaffolding companies and industrial service providers. It provides a safe assembly transport of scaffolding parts by delivering parts just-in-time and just-in-place during assembly. The company was founded in 2016 and is based in Gilching, Germany.

NavVis

Series B in 2015
NavVis is the leading global provider of indoor spatial intelligence solutions for enterprises, trusted by top companies including Daimler, Allianz, Huawei, Lenovo and Deutsche Telekom. NavVis helps enterprises drive efficiencies and optimize business performance through its open digital twin platform that enables accurate mapping at unprecedented speed and scale, immersive 3D visualization designed for collaboration and location-based apps that pioneer AI-powered positioning technology. Founded in 2013, NavVis is headquartered in Munich and has offices in New York and Shanghai.

Siltectra

Series B in 2015
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.

KONUX

Series A in 2016
KONUX is a German AI scale-up, transforming railway operations for a sustainable future. We combine Machine Learning and IoT to make railway the mobility choice of tomorrow by increasing capacity, reliability, and cost-efficiency. Since its foundation in 2014, KONUX has raised more than $50 million from world-leading investors, expanded to multiple countries in Europe and Asia, and was selected by the World Economic Forum (WEF) as one of the world’s 30 most innovative start-ups and scale-ups worldwide.

NFON

Venture Round in 2010
NFON AG, a Munich, Germany-based provider of outsourced telephone systems. nfon's outsourced telephone systems, called IP Centrex, are offered as a complete package from a single source. Operated by a fully redundant, high-performance computer centre and with more than 100 functions, the solution is designed to enable companies of all sizes to save up to 50% percent of the costs for a conventional phone system.

Liva Healthcare

Series A in 2019
Founded in 2014, Liva Healthcare is an innovative digital health coaching platform for scalable lifestyle and disease management. Winner of 'Health IT Firm of the Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe' at the Global Health & Pharma Awards 2018, Liva Healthcare is used by public healthcare, private insurance and pharma companies including NHS England and AXA PPP Healthcare. Liva Healthcare’s platform facilitates ongoing personalised health coaching through an intuitive app, building strong bond between coach, GP and patient. Its focus lies on tackling chronic illnesses, such as Type 2 diabetes, obesity and heart disease by driving behaviour change. The app is multilingual across several languages, proven to work efficiently across all socio-economic backgrounds and is capable of engaging groups normally hard to reach. It is based upon nine to 18 months of continuous patient engagement to make new habits and behaviours stick. One coach can manage 500 patients per year simultaneously without the loss of patient outcomes. Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform or as a turn-key solution, dependent on client specifications. Liva Healthcare has offices in Copenhagen, Denmark and London, UK.

Corimmun

Series B in 2010
Corimmun is a clinical drug developing company located in Martinsried near Munich, Germany, and is focused on novel therapeutics and diagnostics for heart and vascular diseases. Corimmun's activities and experiences comprise all steps from research to drug development and commercialization.

IDENT Technology

Venture Round in 2010
IDENT Technology AG provides technology solutions for working with e-fields in near-field communication and gesture controlled human-machine-interface. It markets its SKINPLEX technologies for detection, interaction, and identification applications in the capacitive near field and the gesture supported human-machine control applications in the form of licenses. The company offers SKINPLEX GestIC for gesture detection applications; SKINPLEX zeropower sensor system, a quasi powerless near-field transponder system for touchless sensing applications in rough environments; and SKINPLEX ultra-low-power proximity system, which provides the solution to wake-up and power down devices on the approach and the departure of the user. It serves consumer electronics, white good, building management, health care, telecommunication, gaming, toys, and automotive Industries. The company was founded in 2002 and is based in Wessling, Germany.

KONUX

Series A in 2017
KONUX is a German AI scale-up, transforming railway operations for a sustainable future. We combine Machine Learning and IoT to make railway the mobility choice of tomorrow by increasing capacity, reliability, and cost-efficiency. Since its foundation in 2014, KONUX has raised more than $50 million from world-leading investors, expanded to multiple countries in Europe and Asia, and was selected by the World Economic Forum (WEF) as one of the world’s 30 most innovative start-ups and scale-ups worldwide.

Hemovent

Series A in 2017
​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop an innovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.

NavVis

Venture Round in 2021
NavVis is the leading global provider of indoor spatial intelligence solutions for enterprises, trusted by top companies including Daimler, Allianz, Huawei, Lenovo and Deutsche Telekom. NavVis helps enterprises drive efficiencies and optimize business performance through its open digital twin platform that enables accurate mapping at unprecedented speed and scale, immersive 3D visualization designed for collaboration and location-based apps that pioneer AI-powered positioning technology. Founded in 2013, NavVis is headquartered in Munich and has offices in New York and Shanghai.

Efficient Energy

Venture Round in 2017
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

Innatera

Seed Round in 2020
Innatera Nanosystems B.V. develops microprocessors that mimic the brain’s mechanisms for processing fast information streams from multiple sensors. The company is based in Delft, the Netherlands.

IQM Finland Oy

Series A in 2020
IQM Finland Oy develops and manufactures hardware systems for quantum computing solutions for practical applications. The company manufactures quantum processors for quantum computers. IQM Finland Oy was founded in 2018 and is headquartered in Espoo, Finland.

KEWAZO

Seed Round in 2020
KEWAZO GmbH develops robotics systems that enable the autonomous transport of materials on the construction site in vertical and horizontal dimensions for large scaffolding companies and industrial service providers. It provides a safe assembly transport of scaffolding parts by delivering parts just-in-time and just-in-place during assembly. The company was founded in 2016 and is based in Gilching, Germany.

AFFiRiS

Venture Round in 2017
AFFiRiS AG develops and manufactures peptide-based vaccines for therapeutic treatment of chronic diseases with unmet medical needs. Its development portfolio includes vaccines against Alzheimer’s disease, Parkinson’s disease and atherosclerosis, multiple system atrophy, hypertension, diabetes, psoriasis, allergies, asthma, Huntington’s disease, and other diseases. The company was founded in 2003 and is based in Vienna, Austria.

Efficient Energy

Venture Round in 2013
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

Isarna Holding GmbH

Venture Round in 2010
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Siltectra

Series B in 2016
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.

LXP Group GmbH

Series A in 2017
LXP Group develops LX-Process. The LX-Process cracks 2G biomass and can readily be adapted for large-scale 2G ethanol manufacturing but is also inversely scalable, enabling economic retrofit of smaller, decentralized biogas plants. Also, the LX-Process eliminates a principle hurdle faced in bio-processing, namely the presence / concentration of inhibitors, which are formed in all existing 2G pre-treatment methods.

Bolt

Venture Round in 2021
Second Closet facilitates the pickup, storage, and return of customer belongings on schedule. Second Closet enables customers to schedule and book storage spaces and have their storage boxes, item pickup, and return transport as per their requirement. Second Closet's service is secure, convenient, and affordable. It is headquartered in Toronto, Ontario in Canada.

Protagen

Venture Round in 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Bolt

Series B in 2021
Second Closet facilitates the pickup, storage, and return of customer belongings on schedule. Second Closet enables customers to schedule and book storage spaces and have their storage boxes, item pickup, and return transport as per their requirement. Second Closet's service is secure, convenient, and affordable. It is headquartered in Toronto, Ontario in Canada.

Siltectra

Series B in 2017
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.

SuppreMol

Series C in 2010
SuppreMol is a privately held biotechnology company that pioneers a novel approach for the treatment of autoimmune diseases which could lead to the cure of these disorders instead of merely treating their symptoms.

Efficient Energy

Venture Round in 2020
Efficient Energy GmbH engages in the development, manufacturing, and distribution refrigeration systems for industrial and home applications in Germany and internationally. The company offers eChiller, a clean compression refrigeration unit that uses pure water (R718) as a refrigerant used for removing heat from server rooms and computing centers, as well as continuous industrial processes. It also provides consulting, planning, commissioning, installation, warranty, maintenance, energy efficiency optimization, and remote monitoring services. The company was founded in 2006 and is based in Feldkirchen, Germany.

AMSilk

Series C in 2021
AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.

Isarna Holding GmbH

Venture Round in 2014
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

GWA Hygiene

Venture Round in 2018
GWA Hygiene GmbH manufactures monitoring system for measuring hand hygiene. It manufactures sensors to monitor the hygiene standards of the hospital personnel. GWA Hygiene GmbH also develops a software application to support its hardware and is used to see how the disinfection rates per ward, donor and professional groups develop. The company was founded in 2015 and is based in Stralsund, Germany.

Ganymed Pharmaceuticals

Series E in 2013
Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Isarna Holding GmbH

Venture Round in 2014
Isarna Therapeutics has an unmatched commitment to developing TGF-B inhibitors that stimulate the human immune system to effectively fight cancer. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.

Protagen

Venture Round in 2008
Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases. The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.

Siltectra

Series B in 2017
SILTECTRA GmbH develops and manufactures laser-based wafering technology solutions and services to semiconductor manufacturers. It offers silicon carbide for splitting crystalline materials, gallium nitride (GaN), and sapphire. The company develops cold split technology to process crystal material. The company's technology can be applied with the semiconductor material SiC for use in solar inverters. The company was founded in 2010 and is based in Dresden, Germany. SILTECTRA GmbH operates as a subsidiary of Infineon Technologies AG.